Company / Return on Assets (ROA)
Editas Medicine, Inc. Return on Assets (ROA) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-127.1%
FY2025
5-year range
-127.1% / -19.7%
FY2021-FY2025
Trend
-97.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Assets (ROA) has declined for 5 consecutive years, from -19.2% in FY2020 to -127.1% in FY2025.
Based on SEC 10-K filings.
-127.1% in FY2025 with a 5-year CAGR of -107.9%.
Declined from -38.6% to -127.1% over the past 2 years.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- -104.5pp
- 5-Year Change
- -107.9pp
- 10-Year Change
- -
Key checks
Key Insights
- Editas Medicine, Inc.'s return on assets (roa) has declined for 5 consecutive years.
- In FY2025, return on assets (roa) decreased 97.0% year-over-year.
- Peak return on assets (roa) was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -127.1% | -97.0% |
| FY2024 | -64.5% | -67.3% |
| FY2023 | -38.6% | -71.0% |
| FY2022 | -22.6% | -14.2% |
| FY2021 | -19.7% | -2.8% |
| FY2020 | -19.2% | +18.8% |
| FY2019 | -23.6% | -2.2% |
| FY2018 | -23.1% | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026